CClinicalTrials.gg
CompletedNCT07130591Updated Aug 26, 2025

Efficiency of CogniPlat on Cognitive Functions in Older Adults

An interventional study of Cogniplat game platform and Control group in Mild Cognitive Impairment, sponsored by Izmir Democracy University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 65 Years to 78 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-26.

Sponsored by Izmir Democracy University · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 2 years 6 months after the study started (first participant enrolled Jan 2023, registered Aug 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
65 Years to 78 Years
Sex
All
01

Study summary

Mild cognitive impairment is a common intermediate stage between normal aging and dementia, affecting memory and other cognitive domains in older adults. While pharmacologic treatments lack strong evidence, exercise, cognitive training, and game-based interventions have shown positive effects on cognitive functions. The Cogniplat gaming platform, designed to improve cognitive abilities through personalized, multidisciplinary game exercises, has not yet been clinically evaluated. The present study aims to assess the effectiveness of Cogniplat in enhancing cognitive functions in geriatric individuals.

Read the detailed description

Mild cognitive impairment may occur with physiological aging in geriatric individuals. This describes an intermediate stage from normal cognitive status to dementia. In mild cognitive impairment, there is cognitive impairment in both memory and non-memory domains. Anxiety, depression and other adverse mental health conditions also lead to decreased cognitive functioning. The risk of mild cognitive impairment turning into dementia is quite high. Therefore, diagnosis, follow-up and treatment are important issues. Mild cognitive impairment is common in geriatric populations. Its prevalence increases with age and low education level. The incidence of mild cognitive impairment in geriatric individuals aged 65 years and older is 15-20%.

There is no high quality evidence showing the efficacy of pharmacologic agents in the treatment of mild cognitive impairment. There are also studies showing that exercise and cognitive training have an improving effect on cognitive functions. Cognitive games also have a stimulating effect on memory and communication in these individuals. Game-based education reduces the risk of mild cognitive impairment and depression by stimulating the cerebral cortex and also motivates older adults to participate in treatment. Computer-based cognitive gaming training has been found to have positive effects on attention ability and memory development in this population.

The Cogniplat game platform used in the study is a rehabilitation tool developed to improve the cognitive functions of elderly individuals. Cogniplat is based on a multidisciplinary approach combining theories from neuropsychology, cognitive linguistics and speech therapy. It focuses on improving cognitive functions through different game exercises. In addition, Cogniplat automatically adjusts the difficulty and type of exercises by detecting the cognitive needs of individuals. In the literature, the Cogniplat game platform has been developed, but no studies evaluating its effectiveness have been found. Therefore, the present study was planned to examine the effect of the "Cogniplat" game platform on cognitive functions in geriatric individuals.

02

Conditions studied

  • Mild Cognitive Impairment

Keywords

  • cogniplat
  • geriatric rehabilitation
  • cognitive games
03

In context

Cognitive Dysfunction

3,843 studies on the registry are indexed under Cognitive Dysfunction; 1,100 are open to participants now.

This study's enrollment of 100 is above the median of 65 across 2,808 interventional studies indexed under Cognitive Dysfunction.

Browse Cognitive Dysfunction studies →

Lead sponsor

Izmir Democracy University is the lead sponsor of 73 studies on the registry; 32 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • To volunteer to participate in the study
  • To be over 65 years old
  • had a mini-mental test score above 24
  • could use smartphones and tablets
  • To have sufficient reading and writing skills to use the gaming platform
  • To have good cooperation skills and not have a disease causing vision loss

Exclusion criteria

Exclusion Criteria:

  • Individuals with orthopedic or neurological conditions that prevent the use of a tablet with the upper extremities
  • Individuals who are unable to maintain sitting balance
  • Individuals with hearing loss that may prevent them from hearing information related to the gaming platform
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Play Group

    Group of patients treated with the Cogniplat gaming platform

    Other: Cogniplat game platform

  • Other
    Control Group

    Individuals in this group did not participate in any regular play program

    Other: Control group

Interventions

  • OtherCogniplat game platform

    The Cogniplat gaming platform is designed to improve cognitive function in geriatric individuals, with or without mild cognitive impairment. Participants played the Cogniplat games face-to-face with a physiotherapist twice a week on non-consecutive days for 10 weeks, sessions lasting about 30-45 minutes. Scores from the platform were recorded to evaluate progress.

    Also known as: CGP

  • OtherControl group

    Individuals in this group did not participate in any regular play program. Demographic data were recorded. For evaluation purposes, a single session of Cogniplat game platform was applied in the first interview and in the second interview 10 weeks later. Initial and final evaluations were recorded.

    Also known as: CG

06

What researchers measure

Primary outcomes

  1. Mini-Mental Test

    The Mini-Mental Test consists of eleven items under five main headings: orientation, recording memory, attention and calculation, recall and language, and is evaluated on a total of 30 points. A score of 23/24 is accepted as the threshold for the diagnosis of mild dementia in Turkish elderly

    Time frame: At baseline and 10 week after

  2. Game Platform Scoring

    For each game played on the platform, game duration, accuracy and speed variables were recorded on the servers connected to the platform. Individuals in both the study and control groups played a game on the platform, and the score of this game was recorded on the system and used in the analysis.Game duration, accuracy and speed will be aggregated into a single game performance score automatically generated by the platform and recorded for analysis

    Time frame: At baseline and 10 week after

07

Study locations

1 site
  • Izmir Democracy Univercity
    Izmir, 35000, Turkey (Türkiye)
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07130591
Lead sponsor
Izmir Democracy University
Responsible party
Ferruh Taşpınar (Prof. Dr., Izmir Democracy University) — Principal investigator
First posted
Aug 19, 2025
Start date
Jan 15, 2023
Primary completion
May 15, 2023
Completion
Nov 15, 2023
Last update
Aug 26, 2025

Study contacts

Betül Taspinar, Prof.Dr.
principal investigator · Izmir Democracy University
Ayşe Sezgi Kızılırmak Karataş, Pt.PhD
principal investigator · Izmir Democracy University
Nuri Üçler, Msc.Pt.
principal investigator · Ege University
Ebru Köse, Pt.PhD
principal investigator · Izmir Democracy University
Cansu Ozdemir, Msc.Pt
principal investigator · Izmir Democracy University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion